Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017) Save

Therapeutic updates are periodic reports that feature commentary, insight and review from leading experts on advances in therapeutics in rheumatology. These updates may feature new drug approvals or indications; product label or safety updates, new important clinical trial results, new treatment guidelines or disease management reviews. 

In this Therapeutic Update Drs. Cush and Gibofsky answer 5 questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis (PsA). The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA.